8-K: Serina Therapeutics CEO to Present at Jones Healthcare and Technology Innovation Conference, Highlighting POZ Platform

Serina Therapeutics' CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, showcasing the company's POZ Platform drug optimization technology.

Summary

• Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and other indications.
• The company's POZ Platform aims to improve the efficacy and safety of small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs).
• Steve Ledger, Serina's CEO, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, in Las Vegas.
• The presentation will cover the POZ Platform and its potential applications.
• Serina's lead program, SER-252, is expected to enter clinical trials in Q4 2025 as a treatment for advanced Parkinson's disease, with a potential peak US sales of $2 billion.
• Serina has partnered with Pfizer in the RNA vaccine field.
• The company's POZ technology addresses limitations of other biocompatible polymers, enabling greater drug loading and controlled release.
• SER-252 (POZ-Apomorphine) aims to provide continuous dopaminergic stimulation for Parkinson's patients without adverse skin reactions or the need for continuous infusion.
• The company is targeting a 505(b)(2) NDA regulatory pathway for SER-252, potentially leading to a market launch in 2030.
• Serina is also developing POZ-based delivery platforms for RNA therapeutics and ADCs, with partnerships planned in these areas.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Serina Therapeutics, highlighting the potential of its POZ platform and lead program SER-252. The partnership with Pfizer and the differentiated TPP enabled by POZ + partnership with Enable Injections are also positive signals. However, the company is still in early stages of clinical development, and there are inherent risks associated with drug development and regulatory approvals.

Positives

• The POZ platform has the potential to improve the efficacy and safety of multiple drug modalities.
• SER-252 addresses a large unmet need in advanced Parkinson's disease with a potential $2.1B to $3.3B peak sales opportunity (US / EU / UK).
• The 505(b)(2) regulatory pathway offers a potentially faster and less costly route to market for SER-252.
• The partnership with Enable Injections provides a differentiated and patient-friendly delivery method for SER-252.
• The Pfizer partnership validates the potential of the POZ platform in RNA delivery.
• Insider ownership of 47% aligns management's interests with shareholders.

Negatives

• The company is still in the early stages of clinical development, with SER-252 expected to enter Phase 1 trials in Q4 2025.
• The success of SER-252 and other pipeline candidates is subject to clinical trial risks and regulatory approvals.
• The company faces competition from other companies developing treatments for Parkinson's disease and RNA delivery technologies.
• The forward-looking statements in the presentation are subject to various risks and uncertainties, and actual results may differ materially.

Risks

• Clinical trial results may not be favorable.
• There are uncertainties inherent in the product development process, including the timing of results.
• The company's ability to recruit and enroll suitable patients in clinical trials is a risk.
• Regulatory authorities may not approve the company's product candidates.
• The company faces competition from other biotechnology companies.
• There are uncertainties regarding intellectual property protection.
• The company's cash resources may not be sufficient to fund its operations.

Future Outlook

Serina anticipates several value-driving milestones, including IND submission for SER-252 in Q2 2025, initiation of Phase 1 trials in Q4 2025, and interim data readouts in 2026. The company also plans to pursue POZ platform partnerships in RNA and ADCs in 2025/26.

Management Comments

• Steve Ledger, the Company's Chief Executive Officer, will be presenting at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025.

Industry Context

The presentation highlights Serina's efforts to address unmet needs in Parkinson's disease, where current treatments have limitations. The company is also positioning its POZ platform as a potential alternative to PEGylation in RNA delivery, a field dominated by companies like Pfizer and BioNTech. The market for advanced Parkinson's therapies is growing, with analysts projecting large sales for continuous dopaminergic stimulation (CDS) treatments.

Comparison to Industry Standards

• Current treatments for advanced Parkinson's disease, such as ProDuopa (Abbvie), Vyalev (Abbvie), and Apo-go / Onapgo (Supernus), rely on electronic infusion devices that must be worn daily.
• SER-252 aims to offer a less invasive alternative with less frequent dosing (2x per week) using the Enable Injections enFuse device.
• The company is targeting a similar market share to existing infusion treatments, with a potential peak sales of $2.1B to $3.3B.
• In the RNA delivery space, Serina's POZ-dma LNP is positioned as a potential replacement for PEG-dma LNP (used in the Pfizer/BioNTech COVID-19 vaccine) to reduce reactogenicity.
• The company's partnership with Pfizer suggests a potential advantage over other companies developing RNA delivery technologies.

Stakeholder Impact

• Shareholders: Potential for significant returns if SER-252 and other pipeline candidates are successful.
• Patients: Potential for improved treatment options for Parkinson's disease and other indications.
• Employees: Opportunity to work on innovative drug development programs.
• Partners: Potential for collaboration and licensing opportunities with Serina's POZ platform.

Next Steps

• IND submission with FDA (2Q 2025).
• FDA allowance for Phase 1 trial of SER-252 in Advanced Parkinsons (3Q 2025).
• Initiation of Phase 1 trial of SER-252 in Advanced Parkinsons Disease (4Q 2025).
• New POZ small molecule conjugate IND enabling studies initiated (4Q 2025).
• Interim SER-252 Ph 1 readout (injection site reaction) (2Q 2026).
• Interim SER-252 Ph 1 SAD clinical data readout (3Q 2026).
• Final SER-252 Ph 1 SAD/MAD clinical data readout (2Q 2027).
• POZ platform partnerships in RNA and ADCs (2025/26).

Key Dates

Keywords

POZ Platform, Serina Therapeutics, Parkinson's disease, Apomorphine, RNA therapeutics, ADC, Drug delivery, Clinical trials, SER-252, Pfizer, Enable Injections